PMID- 23165919
OWN - NLM
STAT- MEDLINE
DCOM- 20130822
LR  - 20131121
IS  - 1520-6394 (Electronic)
IS  - 1091-4269 (Linking)
VI  - 30
IP  - 3
DP  - 2013 Mar
TI  - Val66Met BDNF genotypes in melancholic depression: effects on brain structure and 
      treatment outcome.
PG  - 225-33
LID - 10.1002/da.22025 [doi]
AB  - BACKGROUND: A brain-derived neurotrophic factor (BDNF) prodomain 
      single-nucleotide polymorphism resulting in a valine to methionine substitution 
      (Val66Met) has been associated with depression-related phenotypes and brain 
      alterations involving regions consistently associated with major depressive 
      disorder (MDD). The aim of our study was to evaluate the association of regional 
      gray matter (GM) volume within the hippocampus and other unpredicted regions at 
      the whole-brain level with the BDNF Val66Met polymorphism in MDD patients with 
      melancholic features and their impact on treatment outcome. METHODS: A sample of 
      37 MDD inpatients was assessed with three-dimensional magnetic resonance imaging 
      (1.5-T scanner). GM volume was analyzed with voxel-based morphometry (VBM) using 
      Statistical Parametric Mapping (SPM5). The BDNF Val66Met variant was genotyped 
      using SNPlex technology. MDD patients were classified according to genotype 
      distribution under a dominant model of inheritance and thus comparing Val66 
      homozygotes (n = 22) versus Met66 carriers (n = 15). RESULTS: A significant GM 
      volume reduction in the left hippocampus was observed in Met66 carriers. 
      Conversely, in the same group, a volume increase in the right orbitofrontal 
      cortex was detected. Moreover, a significant negative correlation between left 
      hippocampal volume and days to remission was found in Val66 homozygotes, whereas 
      right orbitofrontal volume was inversely correlated to days to remission in Met66 
      carriers. CONCLUSIONS: Our results suggest that the Val66Met BDNF variant may 
      have a differential impact on the brain structure of melancholic patients with 
      possible treatment outcome implications.
CI  - (c) 2012 Wiley Periodicals, Inc.
FAU - Cardoner, Narcis
AU  - Cardoner N
AD  - Department of Psychiatry, Bellvitge University Hospital-IDIBELL, Feixa Llarga 
      s/n, Barcelona, Spain. ncardoner@bellvitgehospital.cat
FAU - Soria, Virginia
AU  - Soria V
FAU - Gratacos, Monica
AU  - Gratacos M
FAU - Hernandez-Ribas, Rosa
AU  - Hernandez-Ribas R
FAU - Pujol, Jesus
AU  - Pujol J
FAU - Lopez-Sola, Marina
AU  - Lopez-Sola M
FAU - Deus, Joan
AU  - Deus J
FAU - Urretavizcaya, Mikel
AU  - Urretavizcaya M
FAU - Estivill, Xavier
AU  - Estivill X
FAU - Menchon, Jose M
AU  - Menchon JM
FAU - Soriano-Mas, Carles
AU  - Soriano-Mas C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121116
PL  - United States
TA  - Depress Anxiety
JT  - Depression and anxiety
JID - 9708816
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - AE28F7PNPL (Methionine)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amino Acid Substitution/*genetics
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Cerebral Cortex/*pathology
MH  - Depressive Disorder, Major/classification/*genetics/*pathology
MH  - Female
MH  - Genetic Variation
MH  - Genotype
MH  - Humans
MH  - Imaging, Three-Dimensional/instrumentation/methods
MH  - Magnetic Resonance Imaging/instrumentation/methods
MH  - Male
MH  - Methionine/genetics
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Treatment Outcome
MH  - Valine/genetics
EDAT- 2012/11/21 06:00
MHDA- 2013/08/24 06:00
CRDT- 2012/11/21 06:00
PHST- 2012/07/11 00:00 [received]
PHST- 2012/10/07 00:00 [revised]
PHST- 2012/10/18 00:00 [accepted]
PHST- 2012/11/21 06:00 [entrez]
PHST- 2012/11/21 06:00 [pubmed]
PHST- 2013/08/24 06:00 [medline]
AID - 10.1002/da.22025 [doi]
PST - ppublish
SO  - Depress Anxiety. 2013 Mar;30(3):225-33. doi: 10.1002/da.22025. Epub 2012 Nov 16.